A5012471769- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Global Cancer Incidence and Screening
- Acute Myeloid Leukemia Research
- Cancer Risks and Factors
- Lung Cancer Treatments and Mutations
- Neutropenia and Cancer Infections
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Acute Lymphoblastic Leukemia research
- PARP inhibition in cancer therapy
- Colorectal Cancer Screening and Detection
- Breast Lesions and Carcinomas
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Chronic Myeloid Leukemia Treatments
- COVID-19 and healthcare impacts
Swedish Medical Center
2015-2025
Providence College
2021-2025
Cancer Institute (WIA)
2013-2024
Seattle University
1975-2023
Swedish Medical Center
2005-2022
St. Joseph Health System
2021
eHealth Consulting (United States)
2020
University of Washington
1979-2013
FIT Consulting (Italy)
2013
Mayo Clinic in Arizona
2009
The genetic and clinical heterogeneity of breast cancer makes the identification effective therapies challenging. We designed I-SPY 2, a phase multicenter, adaptively randomized trial to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for cancer. goal is match responding subtypes. report results veliparib, poly(ADP-ribose) polymerase (PARP) inhibitor, combined carboplatin.In this ongoing trial, women are eligible participation if they have stage II...
The heterogeneity of breast cancer makes identifying effective therapies challenging. I-SPY 2 trial, a multicenter, adaptive phase trial neoadjuvant therapy for high-risk clinical stage II or III cancer, evaluated multiple new agents added to standard chemotherapy assess the effects on rates pathological complete response (i.e., absence residual in lymph nodes at time surgery).We used randomization compare plus tyrosine kinase inhibitor neratinib with control. Eligible women were categorized...
Lenalidomide is a novel immunomodulatory agent with antiproliferative activities. Given its efficacy in wide range of hematologic malignancies, we conducted phase II trial (NHL-001) single-agent lenalidomide indolent non-Hodgkin's lymphoma (NHL).Patients relapsed/refractory NHL were eligible, no limit on the number previous therapies. Oral 25 mg was self-administered once daily days 1 to 21 every 28-day cycle for up 52 weeks as tolerated, or until disease progression. The primary end point...
Differences in de novo (dnMBC) and recurrent metastatic breast cancer (rMBC) presentation survival over time have not been adequately described. A retrospective cohort study, 1990–2010, with follow up through 2015 of dnMBC patients (stage IV at diagnosis) rMBC subsequent distant recurrence I–III initial [dnMBC = 247, 911)]. Analysis included Chi squared tests categorical variables, Kaplan–Meier estimates, Cox proportional adjusted hazard ratios (HzR) 95% confidence intervals (CI). Disease...
The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 combination with standard therapy patients high-risk early-stage cancer.I-SPY 2 multicenter, phase II, open-label, adaptively randomized neoadjuvant platform trial that screens experimental therapies efficiently identifies potential predictive biomarker signatures. Patients are categorized by human epidermal...
Abstract: Triple negative (TN) [estrogen receptor (ER), progesterone (PgR)] (ER−/PgR−/Her2/neu−) breast cancer (BC) is an aggressive disease without tumor-specific treatment options. Our objective to evaluate the relative contribution of combined Her2/neu (Her2) and hormone (HR) status BC progression. A prospective primary cohort 1550 patients at our institution, stage I–IV, from 1998 2003 were categorized by HR Her2 into ER+/PgR+/Her2− (HR+/Her2−) (n = 1134), ER+/PgR+/Her2+ [triple positive...
To analyze trends in detection method related to breast cancer stage at diagnosis, treatments, and outcomes over time among 40-49-year-old women.i This study was institutional review board approved, with a waiver of informed consent, HIPAA compliant. A longitudinal prospective cohort conducted women aged 40-49 years who had primary cancer, during 1990-2008, were identified tracked by dedicated registry database (n = 1977). Method detection--patient detected (PtD), physician (PhysD), or...
Patients with DLBCL who are ineligible for or have relapsed after aggressive salvage chemotherapy a poor prognosis. CD40 is expressed on multiple B-cell neoplasms including and potential target immunotherapy. Dacetuzumab (SGN-40), non-blocking, partial agonist, humanized IgG1, anti-CD40 monoclonal antibody, has previously demonstrated anti-lymphoma activity in phase I study. A II study was undertaken to evaluate the rate duration of objective responses safety single-agent dacetuzumab DLBCL....
Abstract The many improvements in breast cancer therapy recent years have so lowered rates of recurrence that it is now difficult or impossible to conduct adequately powered adjuvant clinical trials. Given the new drugs and potential synergistic combinations, neoadjuvant approach has been used test benefit drug combinations trials primary cancer. A FDA-led meta-analysis showed pathologic complete response (pCR) predicts disease-free survival (DFS) within patients who specific subtypes. This...
BACKGROUND The extent to which improvements over time in breast cancer survival are related earlier detection by mammography or more effective treatments is not known. METHODS At a comprehensive care center, the authors conducted retrospective cohort study of women ages 50 69 years who were diagnosed with invasive (stages I through III) and followed 3 periods (1990‐1994, 1995‐1999, 2000‐2007). Data abstracted from patient charts included method, diagnosis, treatment, follow‐up for vital...
Nitroblue tetrazolium (NBT) dye reduction by leukocytes of 21 patients receiving prednisone was significantly decreased. Nineteen percent the had values similar to those found in children with chronic granulomatous disease, and 57% heterozygous-range NBT reduction. A qualitative "slide test" correlated well quantitative assay. The uptake particles phagocytes steroid-treated appeared normal. exact mechanism corticosteroid action remains unknown. decreased observed vitro suggests an induced...
Abstract: Adjuvant treatment of T1N0 breast cancer (BC) has evolved in recent years with chemotherapy options dependent on tumor size and cellular characteristics. Our goal is to describe the difference outcome between triple negative (TriNeg) estrogen/progesterone receptor positive/her2/neu-negative BC. From our institute's registry, we identified primary BC patients diagnosed from 1998 2005, (ER−/PR−)/her-2/neu (her2−) (TriNeg = 110) ER+/PR+/her2− (HR+/her2− 919). Clinical diagnosis...
PURPOSE To assess the antiemetic effects and safety profile of four different doses granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis cisplatin-induced nausea vomiting. PATIENTS AND METHODS One hundred eighty-four chemotherapy-naive patients receiving high-dose cisplatin (81 to 120 mg/m2) were randomized receive one (5, 10, 20, or 40 micrograms/kg) before chemotherapy. Patients observed on an...
No AccessJournal of UrologyPediatric urology1 Mar 2008Metastatic Adenocarcinoma After Augmentation Gastrocystoplasty Vijaya M. Vemulakonda, Thomas S. Lendvay, Margarett Shnorhavorian, Byron D. Joyner, Henry Kaplan, Michael E. Mitchell, and Richard W. Grady VemulakondaVijaya Vemulakonda , LendvayThomas Lendvay ShnorhavorianMargarett Shnorhavorian JoynerByron Joyner KaplanHenry Kaplan MitchellMichael Mitchell GradyRichard View All Author...
Our objective was to measure myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) risk associated with radiation and/or chemotherapy breast cancer (BC) treatment. study cohort composed of BC patients diagnosed from 1990 2005 followed up for blood disorders, mean length follow = 7.17 years, range 2-18 years. 5790 TNM stage 0-III treated surgery alone, were included. Patients without (n 111), stem cell transplantation 98), unknown or non-standard regimens 94), lost 66) 'cancer...
To evaluate the characteristics and outcomes of women aged 75 years older with mammography-detected breast cancer, an age group not represented in mammography screening effectiveness studies.We conducted a HIPAA-compliant, prospective cohort study waiver informed consent patients primary older, stage 0-IV disease from 1990 to 2011, identified tracked our registry database (n = 1162). Details including stage, treatment, outcomes, method detection (by patient, physician, or mammography) were...
Abstract Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis proliferation. Trebananib was combined paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients high-risk, early-stage to one of several experimental therapies or control based on receptor subtypes as defined by hormone (HR) HER2 status MammaPrint...
Our objective is to characterize treatment of triple-negative breast cancer (TNBC) in older patients and measure mortality risk relative younger women. We conducted a retrospective cohort study analysis presenting with primary TNBC, age 25-93, stage I-III from 1990 2014, identified tracked by our registry (n=771). Clinical characteristics were chart abstracted at diagnosis follow-up. The Kaplan–Meier method was used disease-specific survival (DSS) Cox regression modeling for contribution...
Background: The aim of this study was to determine the frequency alterations in BRAF and other RAS/RAF genes, as well targetable pathways malignant peripheral nerve sheath tumors (MPNSTs). Patients Methods: Pathology specimens were available for 2 cohorts: (1) patients with MPNST at Swedish Cancer Institute (n=17) from 2004 through 2016, (2) evaluated >300 genomic Foundation Medicine 2014 2016 (n=186; including BRAF-mutated MPNST). Results: Of 201 MPNSTs, 13 (6.5%) demonstrated alterations....
Background The extent of breast cancer outcome disparity can be measured by comparing Surveillance, Epidemiology, and End Results (SEER) cancer‐specific survival (BCSS) region with institutional cohort (IC) rates. Methods Patients who were diagnosed a first primary, de novo, stage IV at ages 25 to 84 years from 1990 2011 studied. change in 5‐year BCSS over time was compared using the SEER 9 registries (SEER 9) without Seattle‐Puget Sound (S‐PS) (n = 12,121), S‐PS alone 1931), IC 261)....
As the coronavirus (COVID-19) epidemic passed initial infection peak in Washington State, phased re-opening lifted stay-at-home orders and restrictions leading to increased non-essential work, social activities gathering, especially among younger persons.A longitudinal cohort analysis of State Department Health COVID-19 confirmed case age distribution 1) March-April 2020 (N = 13,934) 2) March-August 76,032) for proportional change over time using chi square tests significance.From March 1st...
NUT midline carcinoma is a rare malignancy most commonly seen in adolescents and young adults. The disease presents often the lung or head neck area but can be occasionally elsewhere. diagnosis difficult requires high degree of suspicion with demonstration classic fusion rearrangement mutation NUTM1 gene one variety partners by immunohistochemistry, fluorescent situ hybridization, genomic analysis. Survival usually only number months few long-term survivors. Here we report longest-known...